



## Current Agreements

### Dealdoc

#### **Collaborative R&D agreement for antibody-drug conjugate (ADC) technology with antibodies to a single oncology target**

Abbott Laboratories  
Seattle Genetics

Mar 22 2011

# Collaborative R&D agreement for antibody-drug conjugate (ADC) technology with antibodies to a single oncology target

<b>Companies:</b>	<a href="#">Abbott Laboratories</a> <a href="#">Seattle Genetics</a>
<b>Announcement date:</b>	Mar 22 2011
<b>Deal value, US\$m:</b>	453.0 : sum of upfront and milestone payments

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

## Details

<b>Announcement date:</b>	Mar 22 2011
<b>Industry sectors:</b>	Bigpharma Bigbiotech Pharmaceutical Biotech
<b>Therapy areas:</b>	Oncology Antibodies » Antibody-drug conjugate
<b>Technology types:</b>	Biological compounds Enabling technology
<b>Deal components:</b>	Collaborative R&D
<b>Stages of development:</b>	Discovery Preclinical
<b>Geographic focus:</b>	Worldwide

## Financials

<b>Deal value, US\$m:</b>	453.0 : sum of upfront and milestone payments
<b>Upfront, US\$m:</b>	8.0 : upfront payments 25 : sum of upfront fee
<b>Milestones, US\$m:</b>	200.0 : development, regulatory and commercial milestones n/d : annual maintenance fees 220 : sum of potential milestone payments
<b>Royalty rates, %:</b>	n/d : royalties on worldwide net sales of any resulting ADC products
<b>Funding, US\$m:</b>	n/d : research support payments for assistance provided to Abbott under the collaboration

## Termsheet

23 October 2012

Abbott Laboratories will pay a \$25 million upfront fee to Seattle Genetics for expanded rights to utilize Seattle Genetics' technology for cancer.

The expanded collaboration between the two drug companies allows Abbott to gain rights to utilize Seattle Genetics' auristatin-based antibody-drug conjugate technology with antibodies to additional oncology targets.

In addition, Seattle Genetics may receive up to \$220 million in potential milestone payments per additional target upon achieving predetermined objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products under the collaboration.

In addition to the upfront payment and potential milestone payments and royalties, Seattle Genetics will receive annual maintenance fees and research support payments for assistance provided to Abbott under the collaboration.

---

22 March 2011

Collaboration agreement with Abbott under which Abbott will pay an upfront fee of \$8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.

Abbott is responsible for research, product development, manufacturing and commercialization of any ADC products under the collaboration.

Pending achievement of certain development, regulatory and commercial milestones, Seattle Genetics is eligible to receive from Abbott up to approximately \$200 million in milestone payments, as well as royalties on worldwide net sales of any resulting ADC products.

Seattle Genetics also will receive annual maintenance fees and research support payments for assistance provided to Abbott under the collaboration.

## Press Release

23 October 2012

Abbott to Pay \$25 Million Fee to Expand Cancer Technology Rights Deal with Seattle Genetics

Abbott Laboratories (ABT) will pay a \$25 million upfront fee to Seattle Genetics Inc. (SGEN) for expanded rights to utilize Seattle Genetics' technology for cancer.

The expanded collaboration between the two drug companies allows Abbott to gain rights to utilize Seattle Genetics' auristatin-based antibody-drug conjugate technology with antibodies to additional oncology targets.

In addition, Seattle Genetics may receive up to \$220 million in potential milestone payments per additional target upon achieving predetermined objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products under the collaboration.

"ADCs have emerged as an important therapeutic approach to cancer, driven by the FDA approval of Adcetris, and encouraging data from numerous clinical and preclinical ADC programs in development by Seattle Genetics and our collaborators," said Natasha Hernday, vice president of corporate development at Seattle Genetics. "This expanded collaboration with Abbott further validates our technology and approach in targeting and treating cancer."

Antibody-drug conjugates are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. Adcetris is the first drug approved utilizing Seattle Genetics' ADC technology.

Seattle Genetics and Abbott originally entered into an antibody-drug conjugate collaboration in March of last year under which Abbott paid an upfront fee of \$8 million for rights to utilize Seattle Genetics' ADC technology with antibodies to a single oncology target.

Abbott is responsible for research, product development, manufacturing and commercialization of any ADC products under the expanded collaboration.

In addition to the upfront payment and potential milestone payments and royalties, Seattle Genetics will receive annual maintenance fees and research support payments for assistance provided to Abbott under the collaboration.

Shares of Abbott closed at \$65.81 Monday, while those of Seattle Genetics closed at \$26.03. Both companies' stocks were inactive in recent premarket trading.

---

22 March 2011

Seattle Genetics, Inc. (SGEN) Announces Antibody-Drug Conjugate Collaboration with Abbott Laboratories (ABT); Seattle Genetics Gets \$8 Million Upfront; Eligible for as much as \$200 Million 3/22/2011

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN - News) today announced that it has entered into a collaboration agreement with Abbott (NYSE:ABT - News) under which Abbott will pay an upfront fee of \$8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.

"We are pleased to collaborate with Abbott on our ADC technology given their position as one of the world's leading pharmaceutical companies and their demonstrated commitment to both biologic and oncology therapeutics," said Eric L. Dobmeier, Chief Business Officer of Seattle Genetics. "This is the second ADC collaboration with a multinational pharmaceutical company that we have announced this year, further illustrating the important role that our ADC technology is poised to play in the treatment of many types of cancer."

Abbott is responsible for research, product development, manufacturing and commercialization of any ADC products under the collaboration. Pending achievement of certain development, regulatory and commercial milestones, Seattle Genetics is eligible to receive from Abbott up to approximately \$200 million in milestone payments, as well as royalties on worldwide net sales of any resulting ADC products. Seattle Genetics also will receive annual maintenance fees and research support payments for assistance provided to Abbott under the collaboration.

ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic, highly potent cell-killing agents called auristatins (such as MMAE and MMAF) and stable linker systems that attach auristatin to the antibody. Seattle Genetics' novel linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.

Seattle Genetics has 11 active ADC collaborations and has generated more than \$155 million from ADC licensing deals to date. There are currently 11 ADCs in clinical development across both internal and collaborator pipelines using Seattle Genetics' technology.

#### About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company submitted a Biologics License Application to the U.S. Food and Drug Administration for its lead product candidate, brentuximab vedotin, for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma in February 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [www.seattlegenetics.com](http://www.seattlegenetics.com).

#### Filing Data

*Not available.*

#### Contract

*Not available.*